Logo image of SAGE

SAGE THERAPEUTICS INC (SAGE) Stock Fundamental Analysis

NASDAQ:SAGE - Nasdaq - US78667J1088 - Common Stock - Currency: USD

8.68  -0.02 (-0.23%)

After market: 8.685 +0.01 (+0.06%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to SAGE. SAGE was compared to 550 industry peers in the Biotechnology industry. SAGE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, SAGE is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SAGE has reported negative net income.
In the past year SAGE has reported a negative cash flow from operations.
In the past 5 years SAGE reported 4 times negative net income.
In the past 5 years SAGE reported 4 times negative operating cash flow.
SAGE Yearly Net Income VS EBIT VS OCF VS FCFSAGE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M -600M

1.2 Ratios

Looking at the Return On Assets, with a value of -71.22%, SAGE is doing worse than 64.07% of the companies in the same industry.
The Return On Equity of SAGE (-81.68%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -71.22%
ROE -81.68%
ROIC N/A
ROA(3y)-57.96%
ROA(5y)-34.18%
ROE(3y)-65.47%
ROE(5y)-38.73%
ROIC(3y)N/A
ROIC(5y)N/A
SAGE Yearly ROA, ROE, ROICSAGE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60 -80

1.3 Margins

SAGE has a Gross Margin of 45.16%. This is in the better half of the industry: SAGE outperforms 75.50% of its industry peers.
In the last couple of years the Gross Margin of SAGE has declined.
SAGE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 45.16%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.74%
GM growth 5Y-3.93%
SAGE Yearly Profit, Operating, Gross MarginsSAGE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

6

2. Health

2.1 Basic Checks

SAGE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SAGE has more shares outstanding
The number of shares outstanding for SAGE has been increased compared to 5 years ago.
SAGE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SAGE Yearly Shares OutstandingSAGE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
SAGE Yearly Total Debt VS Total AssetsSAGE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

Based on the Altman-Z score of -5.35, we must say that SAGE is in the distress zone and has some risk of bankruptcy.
SAGE's Altman-Z score of -5.35 is on the low side compared to the rest of the industry. SAGE is outperformed by 61.52% of its industry peers.
There is no outstanding debt for SAGE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.35
ROIC/WACCN/A
WACC11.13%
SAGE Yearly LT Debt VS Equity VS FCFSAGE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B 2B

2.3 Liquidity

SAGE has a Current Ratio of 9.16. This indicates that SAGE is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 9.16, SAGE is doing good in the industry, outperforming 75.32% of the companies in the same industry.
SAGE has a Quick Ratio of 9.16. This indicates that SAGE is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 9.16, SAGE is in the better half of the industry, outperforming 75.50% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.16
Quick Ratio 9.16
SAGE Yearly Current Assets VS Current LiabilitesSAGE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

More info and screens

6

3. Growth

3.1 Past

SAGE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 43.60%, which is quite impressive.
Looking at the last year, SAGE shows a very negative growth in Revenue. The Revenue has decreased by -27.58% in the last year.
SAGE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 42.99% yearly.
EPS 1Y (TTM)43.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.53%
Revenue 1Y (TTM)-27.58%
Revenue growth 3Y87.07%
Revenue growth 5Y42.99%
Sales Q2Q%265.84%

3.2 Future

SAGE is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.71% yearly.
SAGE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 40.01% yearly.
EPS Next Y44.26%
EPS Next 2Y24.68%
EPS Next 3Y19.27%
EPS Next 5Y13.71%
Revenue Next Year93.34%
Revenue Next 2Y66.24%
Revenue Next 3Y54.03%
Revenue Next 5Y40.01%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
SAGE Yearly Revenue VS EstimatesSAGE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
SAGE Yearly EPS VS EstimatesSAGE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5 10 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SAGE. In the last year negative earnings were reported.
Also next year SAGE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SAGE Price Earnings VS Forward Price EarningsSAGE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SAGE Per share dataSAGE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

SAGE's earnings are expected to grow with 19.27% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.68%
EPS Next 3Y19.27%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SAGE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SAGE THERAPEUTICS INC

NASDAQ:SAGE (7/30/2025, 8:00:02 PM)

After market: 8.685 +0.01 (+0.06%)

8.68

-0.02 (-0.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-30 2025-07-30/amc
Earnings (Next)10-27 2025-10-27/bmo
Inst Owners80.99%
Inst Owner Change3.81%
Ins Owners0.25%
Ins Owner Change-6.59%
Market Cap543.54M
Analysts69.41
Price Target8.67 (-0.12%)
Short Float %3.95%
Short Ratio0.99
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.48%
Min EPS beat(2)0.49%
Max EPS beat(2)18.46%
EPS beat(4)3
Avg EPS beat(4)4.88%
Min EPS beat(4)-1.61%
Max EPS beat(4)18.46%
EPS beat(8)3
Avg EPS beat(8)-5.91%
EPS beat(12)4
Avg EPS beat(12)-4.23%
EPS beat(16)7
Avg EPS beat(16)-3.76%
Revenue beat(2)1
Avg Revenue beat(2)41.33%
Min Revenue beat(2)-2.5%
Max Revenue beat(2)85.16%
Revenue beat(4)2
Avg Revenue beat(4)19.35%
Min Revenue beat(4)-12.99%
Max Revenue beat(4)85.16%
Revenue beat(8)4
Avg Revenue beat(8)11.31%
Revenue beat(12)7
Avg Revenue beat(12)12.94%
Revenue beat(16)7
Avg Revenue beat(16)2.33%
PT rev (1m)-1.66%
PT rev (3m)5.63%
EPS NQ rev (1m)1.96%
EPS NQ rev (3m)-0.7%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.57%
Revenue NQ rev (1m)0.49%
Revenue NQ rev (3m)2.68%
Revenue NY rev (1m)0.93%
Revenue NY rev (3m)-0.06%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.72
P/FCF N/A
P/OCF N/A
P/B 1.47
P/tB 1.47
EV/EBITDA N/A
EPS(TTM)-4.89
EYN/A
EPS(NY)-2.94
Fwd EYN/A
FCF(TTM)-4.62
FCFYN/A
OCF(TTM)-4.62
OCFYN/A
SpS1.12
BVpS5.89
TBVpS5.89
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -71.22%
ROE -81.68%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 45.16%
FCFM N/A
ROA(3y)-57.96%
ROA(5y)-34.18%
ROE(3y)-65.47%
ROE(5y)-38.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.74%
GM growth 5Y-3.93%
F-Score3
Asset Turnover0.17
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.16
Quick Ratio 9.16
Altman-Z -5.35
F-Score3
WACC11.13%
ROIC/WACCN/A
Cap/Depr(3y)40.51%
Cap/Depr(5y)28.52%
Cap/Sales(3y)4.11%
Cap/Sales(5y)3.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.53%
EPS Next Y44.26%
EPS Next 2Y24.68%
EPS Next 3Y19.27%
EPS Next 5Y13.71%
Revenue 1Y (TTM)-27.58%
Revenue growth 3Y87.07%
Revenue growth 5Y42.99%
Sales Q2Q%265.84%
Revenue Next Year93.34%
Revenue Next 2Y66.24%
Revenue Next 3Y54.03%
Revenue Next 5Y40.01%
EBIT growth 1Y32.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year40.48%
EBIT Next 3Y19.55%
EBIT Next 5Y14.35%
FCF growth 1Y45.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.51%
OCF growth 3YN/A
OCF growth 5YN/A